Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed financial performance with declining RMS revenue and increased operating loss, despite some DSA growth. The Q&A highlights concerns about profitability, with management attributing issues to seasonality and costs, but lacking detailed guidance. The debt increase and reduced cash position are worrisome. While there is potential for future growth, the current financials and uncertainties suggest a negative market reaction in the short term.
Key Financial Performance
Total Revenue $120.9 million, an increase of $1 million or 0.8% year-over-year, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue.
DSA Revenue $48 million, up from $42.8 million in Q1 fiscal 2025, driven by an increase in discovery pharmacology service and surgical services revenue as well as increased revenue at the Rockville facility.
RMS Revenue $72.9 million, a decrease of $4.1 million or 5.4% year-over-year, primarily due to lower NHP volumes sold, partially offset by higher average selling prices for NHPs and higher NHP-related services revenue.
Operating Loss $16.3 million, an increase of $0.8 million from $15.5 million in Q1 fiscal 2025, driven by a $2.4 million increase in RMS operating loss, partially offset by a $1.2 million increase in DSA operating income.
DSA Operating Income $8.2 million or 6.8% of total revenue, compared to $7.1 million or 5.9% of total revenue in Q1 fiscal 2025, driven by higher DSA revenue and partially offset by increased costs related to personnel and supplies.
RMS Operating Income $7.2 million or 5.9% of total revenue, compared to $9.4 million or 7.9% of total revenue in Q1 fiscal 2025, with lower margins primarily driven by lower NHP volume sales.
Interest Expense $13.5 million, a decrease from $13.8 million in Q1 fiscal 2025, primarily due to lower interest rates.
Net Loss $28.4 million or $0.83 loss per diluted share, compared to $27.6 million or $1.02 loss per diluted share in Q1 fiscal 2025.
Adjusted EBITDA $1.8 million or 1.5% of total revenue, compared to $2.6 million or 2.2% of total revenue in Q1 fiscal 2025.
Cash and Cash Equivalents $12.7 million as of December 31, 2025, compared to $21.7 million on September 30, 2025.
Total Debt $405.8 million as of December 31, 2025, compared to $402.1 million on September 30, 2025.
Capital Expenditures $5.2 million or approximately 4.3% of total revenue, compared to $4.5 million or 3.7% of revenue in Q1 fiscal 2025, with $3 million related to the RMS site optimization plan.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DSA Revenue Growth: DSA revenue increased 12% year-over-year in Q1 2026, with Discovery and Translational Sciences (DTS) revenues up 26% and safety assessment revenues up 7%.
NAMs Strategy: The company enhanced its New Approach Methods (NAMs) strategy, integrating machine learning tools and access to disease-relevant human tissue to improve discovery efforts and speed up new medicine registration.
Market Demand: Despite slow market demand, the DSA business showed strong performance with a 34% increase in trailing 12-month DSA awards.
Site Optimization: Exited 2 leased facilities as part of the RMS site optimization plan, expected to complete by Q3 2026, aiming to improve margins.
Cost Reduction Initiatives: Focused on reducing costs and optimizing the product and services portfolio to improve financial performance.
Debt Refinancing: Engaged Perella Weinberg Partners to explore debt refinancing alternatives and received a waiver for noncompliance with financial covenant ratios.
Client Satisfaction and Delivery: Focused on enhancing client satisfaction, speed, and delivery while initiating cost reductions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
RMS Business Challenges: The RMS business faced challenges, particularly in the NHP (Non-Human Primates) segment, where lower volume sales negatively impacted revenues and margins. RMS revenue for the first quarter declined by 5.4% compared to the prior year, primarily due to decreased NHP sales.
Debt Refinancing and Financial Covenant Compliance: The company is exploring debt refinancing alternatives and received a waiver for noncompliance with financial covenant ratios under its credit agreement for the first quarter of fiscal 2026. This indicates financial strain and reliance on lender support.
Operating Loss Increase: The overall operating loss for the first quarter of fiscal 2026 increased by $0.8 million compared to the prior year, driven by a $2.4 million increase in RMS operating loss.
Cash Flow and Debt Levels: Cash and cash equivalents decreased from $21.7 million to $12.7 million over the quarter. Total debt increased to $405.8 million, indicating liquidity challenges and high leverage.
Macroeconomic and Market Trends: The company continues to navigate macroeconomic factors and business trends that are negatively affecting the RMS business, including slow market demand.
Site Optimization Costs: The RMS site optimization plan incurred $3 million in capital expenditures during the quarter, contributing to financial strain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DSA Revenue Growth: The company expects continued improvement in DSA margins in future quarters, driven by increased discovery service revenue and operating leverage from added capacity and services developed over the last 18 months.
RMS Business Optimization: The RMS site optimization plan is expected to be completed by the third quarter of fiscal 2026, which should positively impact margins in future periods.
NHP Revenue: The company expects full-year 2026 NHP revenue to remain flat compared to the previous year.
Capital Expenditures: Annual capital expenditures for fiscal year 2026 are expected to be less than 4% of revenue.
Debt Refinancing: The company is actively exploring potential debt refinancing alternatives and remains committed to improving its balance sheet.
NAMs Strategy: The company is enhancing its NAMs strategy to support FDA guidance and industry expectations, aiming to make discovery efforts more human-relevant and accelerate the development of new medicines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the factors affecting profitability, particularly margins in RMS and adjusted EBITDA?
A:Seasonality impacts profitability, with the first quarter being tougher due to university closures, holidays, and weather. Margins were affected by increased costs in goods sold, such as animal costs and tariffs, which were not passed along. Pricing adjustments made last summer will take 9-12 months to reflect in margins. Despite lower NHP volumes, growth in DSA and services helped offset the impact.
Q:Why has DSA awards been trending positively, and how will this translate into DSA growth for 2026?
A:The company attributes positive DSA trends to its smaller size, allowing easier growth, strong customer trust, recurring sales, new customer acquisition, and increased brand recognition. Investments in sales force and scientific innovation are also contributing factors. These efforts are expected to drive DSA growth into 2026.
Q:Why did the DSA revenue conversion rate decline in the first quarter, and does it relate to seasonality or capacity issues?
A:The decline in DSA revenue conversion rate is partly due to seasonality and increased backlog. Discovery services, which have quicker conversion rates, contributed to the decline as some projects had longer lead times and blanket POs. Capacity in discovery services is higher than in safety assessment, which also influenced the results.
Q:What is the impact of lease exits and cost reductions on RMS operating leverage, and when will benefits be realized?
A:Operating leverage benefits were overshadowed by a 25% year-over-year decline in NHP volumes. Cost reductions from closing older, less efficient facilities will be realized in the next quarter. Duplicate facility operations during the transition period also impacted results.
Q:Can you provide more details on new relationships in the NAM side and their impact on revenue?
A:The company is focusing on innovation and R&D to avoid becoming a commodity. Collaborations provide access to tools for matching animal models to human diseases, enhancing the company's capabilities. These efforts are expected to drive future revenue growth.
Q:How did weather impact costs and operations in January?
A:Cold weather affected shipping and customer operations, leading to delays. While the company incurred some additional costs for heating and staff efforts to ensure animal care, these costs were not significant enough to impact overall financials.
Q:What was the magnitude of the decline in NHP volumes year-over-year?
A:NHP volumes declined by approximately 25% year-over-year, impacting operating leverage and efficiency gains.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the new relationships in the NAM side, stating that more information might be shared in a future Investor Day. Additionally, while they acknowledged the impact of weather and seasonality, they did not provide precise data on the financial implications.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors measure
CEO seasonality
Colony service
DSA discovery
DSA period
DSA source
DSA year
DTS revenue
FDA industry
Instructions LifeSci
Investors section
NAMs space
NAMs support
NHP Colony
NHP sale
NHPs volume
NHPs weakness
award
cost reduction
debt
month DSA
optimization plan
phase RMS
release Investors
safety assessment
sale RMS
site optimization
NOTV Transcript
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
Unknown2-9
The earnings call reveals mixed financial performance with declining RMS revenue and increased operating loss, despite some DSA growth. The Q&A highlights concerns about profitability, with management attributing issues to seasonality and costs, but lacking detailed guidance. The debt increase and reduced cash position are worrisome. While there is potential for future growth, the current financials and uncertainties suggest a negative market reaction in the short term.
Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript
Positive12-4
The earnings call reveals improved financial metrics, including increased revenue, reduced net loss, and enhanced cash from operations, indicating strong operational efficiency. Despite a cybersecurity incident, the company maintained a positive trajectory with significant increases in awards and stable pricing. The Q&A section shows optimistic trends in awards and revenue growth, with stabilized margins and reduced costs. Though management was vague on some risks, the overall sentiment is positive, especially with the optimistic guidance and improved performance. This suggests a potential positive stock price movement over the next two weeks.
Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents a mixed sentiment. Financial performance shows positive growth in EBITDA and net new DSA awards, but high interest expenses and declining cash reserves are concerning. The Q&A reveals elevated cancellations and cautious management responses, suggesting uncertainty. Despite growth in new service areas and improved delivery metrics, lack of formal guidance and high cancellations temper optimism. Considering these factors, the stock price reaction is likely to be neutral, with no significant short-term catalysts or market cap information to sway the prediction.
Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. Financial performance shows improvement with reduced operating loss and increased adjusted EBITDA, but cash flow issues and high debt remain concerns. The Q&A reveals cautious optimism with potential margin improvements and stable NHP revenue growth, but uncertainties like NIH funding impacts and slow customer growth persist. Overall, the balanced positives and negatives suggest a neutral sentiment, indicating limited stock price movement over the next two weeks.
NOTV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
